Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Takeda Provides NATPARA Regulatory Update
Details : The CRL indicates that the FDA has completed its review of the NATPARA, is a prescription parathyroid hormone PAS and determined that it cannot be approved in its present form.
Product Name : Natpara
Product Type : Hormone
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Undisclosed
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical | Aarhus University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Treatment With PTH After Sternotomy in Cardiac Surgery Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
November 08, 2011
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Undisclosed
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical | Aarhus University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : NPS PHARMS INC | SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable
HEXT (Hypo EXTended): Effect of PTH on Skeleton in Hypoparathyroidism
Details : Undisclosed
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
September 13, 2010
Lead Product(s) : Parathyroid Hormone
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : NPS PHARMS INC | SHIRE PLC
Deal Size : Inapplicable
Deal Type : Inapplicable